Name	Position	Tenure	Compensation	Ownership
Susanne Lundin	Chief Financial Officer	4.3yrs	no data	no data
Magnus Rasmusson	Chief Technology Officer	5.5yrs	no data	no data
Madelene Persson	Marketing Manager	6.4yrs	no data	no data
Daniel Shnira	C.C.O.	less than a year	no data	no data

4.9yrs

Average Tenure

44.5yo

Average Age

Experienced Management: GENI's management team is considered experienced (4.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Bengt-Arne Molin	Independent Director	5.1yrs	SEK 100.00k	0.055% SEK 393.7k
Hans Krantz	Chairman of the Board	15.6yrs	SEK 200.00k	21.82% SEK 156.9m
Stefan Widen	Independent Director	11.1yrs	SEK 100.00k	no data
Johanna Berlinde	Independent Director	2.1yrs	SEK 100.00k	no data
Erik Ivarsson	Director	3.1yrs	SEK 100.00k	0.11% SEK 819.0k

5.1yrs

Average Tenure

66yo

Average Age

Experienced Board: GENI's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/06/13 05:04
End of Day Share Price	2025/06/13 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Generic Sweden AB is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier Sponsored

Generic Sweden Management

Management criteria checks 2/4

Key information

Recent management updates

Generic Sweden AB, Annual General Meeting, May 15, 2025

Less than half of directors are independent

Owner & Member of the board recently sold kr3.5m worth of stock

Owner & Member of the board recently sold kr3.1m worth of stock

Owner & Member of the board recently sold kr1.4m worth of stock

Owner & Member of the board recently sold kr1.3m worth of stock

Recent updates

An undisclosed buyer acquired 2.85% stake in Generic Sweden AB (OM:GENI) from Hans Krantz ÅKeri Aktiebolag for SEK 19.8 million.

New minor risk - Dividend sustainability

First quarter 2025 earnings: Revenues miss analyst expectations

Now 21% undervalued after recent price drop

Generic Sweden (STO:GENI) Is Increasing Its Dividend To SEK1.60

Upcoming dividend of kr1.60 per share

Generic Sweden's (STO:GENI) Profits May Not Reveal Underlying Issues

Generic Sweden's (STO:GENI) Dividend Will Be Increased To SEK1.60

Dividend increased to kr1.60

Full year 2024 earnings: EPS exceeds analyst expectations

Generic Sweden AB, Annual General Meeting, May 15, 2025

Investor sentiment improves as stock rises 18%

Third quarter 2024 earnings: Revenues in line with analyst expectations

Generic Sweden's (STO:GENI) Profits May Not Reveal Underlying Issues

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 24% undervalued after recent price drop

Now 23% undervalued after recent price drop

Now 20% undervalued

First quarter 2024 earnings: Revenues exceed analyst expectations

Now 23% undervalued

Upcoming dividend of kr1.50 per share

Now 23% undervalued after recent price drop

Some Confidence Is Lacking In Generic Sweden AB (STO:GENI) As Shares Slide 29%

Generic Sweden's (STO:GENI) Solid Earnings May Rest On Weak Foundations

Do Generic Sweden's (STO:GENI) Earnings Warrant Your Attention?

Full year 2023 earnings: EPS misses analyst expectations

Investor sentiment deteriorates as stock falls 16%

Now 25% undervalued

Should You Investigate Generic Sweden AB (STO:GENI) At kr60.20?

Investor sentiment improves as stock rises 16%

Now 22% undervalued

Third quarter 2023 earnings: Revenues exceed analyst expectations

Investor sentiment improves as stock rises 21%

Is Now The Time To Look At Buying Generic Sweden AB (STO:GENI)?

New major risk - Earnings quality

Investor sentiment improves as stock rises 17%

Should You Be Adding Generic Sweden (STO:GENI) To Your Watchlist Today?

Upcoming dividend of kr1.25 per share at 2.9% yield

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment improves as stock rises 21%

Full year 2022 earnings: EPS exceeds analyst expectations

Is Generic Sweden AB (STO:GENI) Potentially Undervalued?

Now 21% undervalued

Now 21% undervalued

Third quarter 2022 earnings: Revenues exceed analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings: Revenues miss analyst expectations

We Ran A Stock Scan For Earnings Growth And Generic Sweden (STO:GENI) Passed With Ease

Investor sentiment deteriorated over the past week

Now 23% undervalued after recent price drop

First quarter 2022 earnings: Revenues miss analyst expectations

Upcoming dividend of kr1.00 per share

A Look At The Intrinsic Value Of Generic Sweden AB (STO:GENI)

Less than half of directors are independent

Is It Time To Consider Buying Generic Sweden AB (STO:GENI)?

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Now 23% undervalued after recent price drop

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Is Now The Time To Put Generic Sweden (STO:GENI) On Your Watchlist?

Investor sentiment improved over the past week

Calculating The Fair Value Of Generic Sweden AB (STO:GENI)

Investor sentiment deteriorated over the past week

Owner & Member of the board recently sold kr3.5m worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Owner & Member of the board recently sold kr3.1m worth of stock